Home Itens selecionados Provedores de dados OAI Créditos Sobre Ajuda

			Busca avançada
	Provedor de dados BJMBR (4) Autor Strauss,B.E. (4) Costanzi-Strauss,E. (2) Barboza Jr.,L.C.M. (1) Bento,R.F. (1) Da-Costa,R.C. (1) Haddad,L.A. (1) Hunger,A. (1) Lezirovitz,K. (1) Mingroni-Netto,R.C. (1) Oiticica,J. (1) Tamura,R.E. (1) Vieira,I.L. (1) Zanatta,D.B. (1) Mais... Palavra-chave Gene therapy (3) Clinical trial (2) Retrovirus (2) Adenovirus (1) Adverse event (1) Animal model (1) Cell cycle (1) Cell transplantation (1) Cochlea (1) Growth arrest (1) Hearing loss (1) Immunotherapy (1) Insertional mutagenesis (1) Interferon-β (1) Ototoxicity (1) P53 (1) Severe combined immune deficiency (1) Stem cell therapy (1) Stem cells (1) Mais... Tipo do documento Info:eu-repo/semantics/article (4) Ano 2020 (1) 2016 (1) 2007 (1) 1999 (1) País Brazil (4) Idioma Inglês (4)		Ordenar por:  Relevância Autor Título Ano Registros recuperados: 4 Primeira ... 1 ... Última Combating oncogene activation associated with retrovirus-mediated gene therapy of X-linked severe combined immunodeficiency BJMBR Strauss,B.E.; Costanzi-Strauss,E.. A successful gene therapy clinical trial that also encountered serious adverse effects has sparked extensive study and debate about the future directions for retrovirus-mediated interventions. Treatment of X-linked severe combined immunodeficiency with an oncoretrovirus harboring a normal copy of the gc gene was applied in two clinical trials, essentially curing 13 of 16 infants, restoring a normal immune system without the need for additional immune-related therapies. Approximately 3 years after their gene therapy, tragically, 3 of these children, all from the same trial, developed leukemia as a result of this experimental treatment. The current understanding of the mechanism behind this leukemogenesis involves three critical and cooperating factors,... Tipo: Info:eu-repo/semantics/article Palavras-chave: Retrovirus; Insertional mutagenesis; Severe combined immune deficiency; Gene therapy; Adverse event; Clinical trial. Ano: 2007 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2007000500002 Efficient retrovirus-mediated transfer of cell-cycle control genes to transformed cells BJMBR Strauss,B.E.; Costanzi-Strauss,E.. The use of gene therapy continues to be a promising, yet elusive, alternative for the treatment of cancer. The origins of cancer must be well understood so that the therapeutic gene can be chosen with the highest chance of successful tumor regression. The gene delivery system must be tailored for optimum transfer of the therapeutic gene to the target tissue. In order to accomplish this, we study models of G1 cell-cycle control in both normal and transformed cells in order to understand the reasons for uncontrolled cellular proliferation. We then use this information to choose the gene to be delivered to the cells. We have chosen to study p16, p21, p53 and pRb gene transfer using the pCL-retrovirus. Described here are some general concepts and specific... Tipo: Info:eu-repo/semantics/article Palavras-chave: Gene therapy; Clinical trial; Retrovirus; Animal model; Cell cycle; Growth arrest. Ano: 1999 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X1999000700016 p19Arf sensitizes B16 melanoma cells to interferon-β delivered via mesenchymal stem cells in vitro BJMBR Da-Costa,R.C.; Vieira,I.L.; Hunger,A.; Tamura,R.E.; Strauss,B.E.. The immune stimulatory and anti-neoplastic functions of type I interferon have long been applied for the treatment of melanoma. However, the systemic application of high levels of this recombinant protein is often met with toxicity. An approach that provides localized, yet transient, production of type I interferon may overcome this limitation. We propose that the use of mesenchymal stem cells (MSCs) as delivery vehicles for the production of interferon-β (IFNβ) may be beneficial when applied together with our cancer gene therapy approach. In our previous studies, we have shown that adenovirus-mediated gene therapy with IFNβ was especially effective in combination with p19Arf gene transfer, resulting in immunogenic cell death. Here we showed that MSCs... Tipo: Info:eu-repo/semantics/article Palavras-chave: Gene therapy; Immunotherapy; Stem cell therapy; Adenovirus; P53; Interferon-β. Ano: 2020 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2020000300601 Transplantation and survival of mouse inner ear progenitor/stem cells in the organ of Corti after cochleostomy of hearing-impaired guinea pigs: preliminary results BJMBR Barboza Jr.,L.C.M.; Lezirovitz,K.; Zanatta,D.B.; Strauss,B.E.; Mingroni-Netto,R.C.; Oiticica,J.; Haddad,L.A.; Bento,R.F.. In mammals, damage to sensory receptor cells (hair cells) of the inner ear results in permanent sensorineural hearing loss. Here, we investigated whether postnatal mouse inner ear progenitor/stem cells (mIESCs) are viable after transplantation into the basal turns of neomycin-injured guinea pig cochleas. We also examined the effects of mIESC transplantation on auditory functions. Eight adult female Cavia porcellus guinea pigs (250-350g) were deafened by intratympanic neomycin delivery. After 7 days, the animals were randomly divided in two groups. The study group (n=4) received transplantation of LacZ-positive mIESCs in culture medium into the scala tympani. The control group (n=4) received culture medium only. At 2 weeks after transplantation, functional... Tipo: Info:eu-repo/semantics/article Palavras-chave: Cochlea; Hearing loss; Stem cells; Cell transplantation; Ototoxicity. Ano: 2016 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2016000400603 Registros recuperados: 4 Primeira ... 1 ... Última

Empresa Brasileira de Pesquisa Agropecuária - Embrapa Todos os direitos reservados, conforme Lei n° 9.610 Política de Privacidade Área restrita		Embrapa Parque Estação Biológica - PqEB s/n° Brasília, DF - Brasil - CEP 70770-901 Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco